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1. Introduction1
Mycoplasma pneumonia is a infection of the lung caused 
by Mycoplasma pneumonia which also can be referred to as 
primary atypical pneumonia. The disease has a slow onset 
on patients accompanied with fever and cough symptoms. 
Patients usually present with a small amount of mucus or 
purulent sputum, consciousness appears bloody sputum 
symptoms. However, patients with pulmonary disease 
signs are not obvious where at serious stage can cause the 
patient’s death. Mycoplasma pneumonia often occurs in 
children and adolescents, the incidence of pneumonia is 
about 15~30% of the probability. Mycoplasma pneumonia 
is one of the common diseases of respiratory tract infec-
tions. Because of its relatively weak immunity and resis-
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tance, children are susceptible to respiratory tract infec-
tions. Azithromycin is a new type of antibiotic with good 
oral absorption, high concentration of tissue and cell, long 
half-life, less adverse reactions and mild [1], has been used 
in the treatment of pediatric respiratory tract infections in 
recent years. In our hospital from April 2013 to December 
2014, there were 55 cases of pediatric respiratory tract in-
fections were treated with azithromycin.
2. Materials and methods
2.1. General information
This study selected 110 patients with respiratory tract in-
fection in our hospital from April 2013 to December 2014 
as a study object including children aged 6 months to 12 
years old, mean age (6.80 + 2.10), which 64 cases of male, 
46 cases of female, 53 cases of acute bronchitis, 29 cases of 
acute tonsillitis, 23 cases of acute pharyngitis, pneumonia 
in 5 cases. All cases are in line with respiratory tract infec-
tion diagnosis standard [2]. The exclusion criteria. Cases 
of the exclusion of immune deficiency, congenital heart 
disease, liver disease and allergic to the great circle of the 
drug in order to ensure that the children were not used an-
tibiotics or traditional Chinese medicine before admission. 
Randomly subject were divided into treatment group and 
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control group where the two groups of age, gender and 
clinical performance were comparable such as no statisti-
cal significance (p > 0.05), 
2.2. Method
2.2.1 Conventional therapy
Two groups were given conventional treatment of phlegm, 
cough, fever, calm. During the treatment period, patients 
were closely monitored with various physiological and bio-
chemical index, before and after the treatment. The detec-
tion of abnormal in blood routine, urine routine, liver and 
renal function was watched and timely adjustment of the 
treatment or dose. Nutrition plus adrenal cortical hormone 
intravenous drip for 3 to 5 days were given as appropriate 
treatment for pleurisy and concurrent asthma and other 
pulmonary complications. Obviously intermittent oxygen 
therapy was given to treat the anoxic person [3].
2.2.2. Contrast therapy
In the control group, 18−25 mg/kg of erythromycin was dis-
solved in 8 mL sterile water, mixed with 5% glucose liquid 
and top up to 100 mL every 2−4 hours per day for 1 weeks.
Treatment group: 8 mg/kg per day injection with 5% 
glucose, by intravenous for every 3−4 hours for one times 
a day, while 8 mg/kg per day was administered orally for 4 
days after discontinuation of the drug.
2.3. Curative effect judgment
Refer to the national Ministry of Health issued in 1993 
and the antibacterial drug clinical research guiding prin-
ciple, grades of evaluation were divided into four stages; (1) 
Healing: symptoms, signs, laboratory and pathogen were 
completely recovered. (2) Effect: condition improved mark-
edly, but the four have a not fully recovered to normal; (3) 
Progress: after the medication condition has improved, but 
obviously not enough, (4) Invalid: no medication after 72 
hours, the patient’s condition was not improved obviously 
and even sicker. The total effective = ( 1 + 2 + 3) / (1 + 2+ 3 
+ 4) * 100%.
2.4. Statistical methods
All the data in this study were processed by SPSS 17.0 sta-
tistical software. The differences between two averages 
were compared using t test, two sample rate or composi-
tion were compared by Chi-Square test. Results ( x  + s) in-
dicated that the difference was statistically significant when 
p < 0.05.
3. Results
Two groups of children with symptoms and signs of im-
provement time comparison. From Table 1, the treatment 
group of children with cough time (4.68 + 0.99) d, time 
to defervescence (2.25 + 0.89) d, and rales disappearance 
time of (3.12 + 0.98) d, while the control group of children 
with cough time is (8.05 + 1.11) d, time to defervescence 
(4.25 + 1.02) d and rales disappearance time (5.86 + 0.84 
d). Comparison of fever, cough and rales between these 
two groups showed that azithromycin group was shorter 
than that of erythromycin group, p < 0.05, suggesting that 
azithromycin group curative effect is better than that of 
erythromycin group (Table 1).
3.2. Clinical comparison of two groups
From the Table 2, the treatment group of children cured 25 
cases, markedly effective in 18 cases, progress in 11 cases 
while in the control group, there was 10 cases for cure, 21 
cases were markedly effective and 17 cases is in progress. 
The total effective rate of azithromycin group was 98.2% 
compared to control group where the total effective rate 
was 87.2%. The effect was better in azithromycin group 
that that of erythromycin group thus indicated that the ef-
ficacy of azithromycin group was better than that of eryth-
romycin group.
3.3. The incidence of adverse reactions in the two 
groups
In treatment group, 2 patients (3.6%) had mild gastrointes-
tinal discomfort, nausea and anorexia, and the symptoms 
were relieved after adjustment. The control group had 9 
cases (16.4%) with obvious digestive tract reaction, such as 
nausea, vomiting, abdominal pain, anorexia, 3 cases were 
relieved and 2 cases were treated with ALT and AST. The 
incidence of adverse reactions of the two groups were 3.6% 
and 16.4% and the difference between the two groups was 
Table 1. The improvement of symptoms and signs in the two groups (d).
Group n Relieve a cough Defervesce Rales
Treatment group 55 4.68 ± 0.99 2.25 ± 0.89 3.12 ± 0.98
Control group 55 8.05 ± 1.11 4.25 ± 1.02 5.86 ± 0.84
p - < 0.05 < 0.05 < 0.05
Table 2. Comparison of the clinical efficacy of the two groups after treatment (n %).
Group n Cure Excellence Progress  Invalid Total effective
Treatment group 55 25 (45.5) 18 (32.7) 11 (20.0) 1 (1.8) 54 (98.2)
Control group 55 10 (18.2) 21 (38.1) 17 (30.9) 7 (12.8) 48 (87.2)
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significant difference p < 0.05.
4. Discussion
Respiratory tract infection in children is more complicated 
with the present of infection of virus or bacterial infection 
where fever and cough are the main symptoms. The tra-
chea and bronchial lumen of children is relatively narrow 
thus make the mucus secretion is little. Due to the cilia 
movement is poor, it will result the lung’s tissues lost its 
elasticity and this will easy to be congested. It is even worst 
when combined with bad air quality where the lung will 
contains less gas and the cough reflex becomes relatively 
weak. Therefore, is very important for early treatment of 
children with respiratory tract infection. Commonly, an-
tibiotics were used in clinic as a comprehensive treatment 
in combating problems with fever and cough. In addition, 
acute upper respiratory tract infection is also a common 
disease of children where it plays a major role in nasal, 
nasopharyngeal and oropharyngeal. Therefore, acute up-
per respiratory tract infection is also known as “acute na-
sopharyngitis”, “acute pharyngitis” and “acute tonsillitis”. 
However, it is more generally known as upper respiratory 
tract infection. Symptoms of nasopharyngeal infection 
usually accompany with complications, and may spread 
to adjacent organs, for example, throat, trachea, lung, oral 
cavity, sinuses, middle ear, eye and neck lymph nodes and 
other parts. In some cases, the symptoms of nasopharynge-
al disease in children are improved or disappeared, but the 
disease complications are still affected or worse. In order 
to improve the efficiency of the treatment, it is convenient 
to do early diagnosis in giving the appropriate treatment to 
the children so the clinical characteristics of upper respira-
tory tract infection can be accurately located and analyzed 
[4].
Azithromycin is a new generation of antibiotics, and the 
antibacterial mechanism of erythromycin is similar to the 
50S subunit of the bacterial ribosome. The inhibition is de-
pends on RNA protein synthesis, long half-life, high tissue 
concentration and absorption with a broad antibacterial 
spectrum. As a result, the effect is relatively high, and the 
side effect is relatively small. Azithromycin curative effect 
was significantly higher than that of erythromycin where 
the cough time, cooling time, rales disappearance time was 
shorter than that of erythromycin thus it adverse reaction 
is lower than that of erythromycin as it is similar with the 
Yin peach report [5]. In summary, the efficacy of azithro-
mycin in treatment of children with respiratory tract infec-
tions was significantly higher than that of erythromycin, 
and the course of treatment is short, the application is sim-
ple, and it is worthy of wide application.
To sum up, the treatment of pediatric respiratory tract 
infection in patients with the implementation of the meth-
od has clinical value which can significantly improve the 
treatment effect, effectively alleviate the clinical symptoms 
and reduce the suffering of children.
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